Literature DB >> 33857425

Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion.

Ester Gangoso1, Benjamin Southgate1, Leanne Bradley1, Stefanie Rus1, Felipe Galvez-Cancino2, Niamh McGivern3, Esra Güç4, Chantriolnt-Andreas Kapourani1, Adam Byron3, Kirsty M Ferguson1, Neza Alfazema1, Gillian Morrison1, Vivien Grant1, Carla Blin1, IengFong Sou1, Maria Angeles Marques-Torrejon1, Lucia Conde5, Simona Parrinello6, Javier Herrero5, Stephan Beck7, Sebastian Brandner8, Paul M Brennan1, Paul Bertone9, Jeffrey W Pollard4, Sergio A Quezada2, Duncan Sproul3, Margaret C Frame3, Alan Serrels10, Steven M Pollard11.   

Abstract

Glioblastoma multiforme (GBM) is an aggressive brain tumor for which current immunotherapy approaches have been unsuccessful. Here, we explore the mechanisms underlying immune evasion in GBM. By serially transplanting GBM stem cells (GSCs) into immunocompetent hosts, we uncover an acquired capability of GSCs to escape immune clearance by establishing an enhanced immunosuppressive tumor microenvironment. Mechanistically, this is not elicited via genetic selection of tumor subclones, but through an epigenetic immunoediting process wherein stable transcriptional and epigenetic changes in GSCs are enforced following immune attack. These changes launch a myeloid-affiliated transcriptional program, which leads to increased recruitment of tumor-associated macrophages. Furthermore, we identify similar epigenetic and transcriptional signatures in human mesenchymal subtype GSCs. We conclude that epigenetic immunoediting may drive an acquired immune evasion program in the most aggressive mesenchymal GBM subtype by reshaping the tumor immune microenvironment.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA methylation; chemokine; epigenetics; glioblastoma; immune evasion; immunoediting; interferon signaling; macrophage; neural stem cell; syngeneic

Year:  2021        PMID: 33857425     DOI: 10.1016/j.cell.2021.03.023

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  44 in total

Review 1.  Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma.

Authors:  Payal B Watchmaker; Maggie Colton; Psalm L Pineo-Cavanaugh; Hideho Okada
Journal:  Curr Opin Oncol       Date:  2022-07-19       Impact factor: 3.915

2.  Elucidating the diversity of malignant mesenchymal states in glioblastoma by integrative analysis.

Authors:  Rony Chanoch-Myers; Adi Wider; Mario L Suva; Itay Tirosh
Journal:  Genome Med       Date:  2022-09-19       Impact factor: 15.266

Review 3.  Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Amy B Heimberger; Peiwen Chen
Journal:  Trends Cancer       Date:  2022-05-24

Review 4.  Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity.

Authors:  Ryan C Gimple; Kailin Yang; Matthew E Halbert; Sameer Agnihotri; Jeremy N Rich
Journal:  Nat Rev Cancer       Date:  2022-06-16       Impact factor: 69.800

5.  Glioma progression is shaped by genetic evolution and microenvironment interactions.

Authors:  Frederick S Varn; Kevin C Johnson; Jan Martinek; Jason T Huse; MacLean P Nasrallah; Pieter Wesseling; Lee A D Cooper; Tathiane M Malta; Taylor E Wade; Thais S Sabedot; Daniel Brat; Peter V Gould; Adelheid Wöehrer; Kenneth Aldape; Azzam Ismail; Santhosh K Sivajothi; Floris P Barthel; Hoon Kim; Emre Kocakavuk; Nazia Ahmed; Kieron White; Indrani Datta; Hyo-Eun Moon; Steven Pollock; Christine Goldfarb; Ga-Hyun Lee; Luciano Garofano; Kevin J Anderson; Djamel Nehar-Belaid; Jill S Barnholtz-Sloan; Spyridon Bakas; Annette T Byrne; Fulvio D'Angelo; Hui K Gan; Mustafa Khasraw; Simona Migliozzi; D Ryan Ormond; Sun Ha Paek; Erwin G Van Meir; Annemiek M E Walenkamp; Colin Watts; Tobias Weiss; Michael Weller; Karolina Palucka; Lucy F Stead; Laila M Poisson; Houtan Noushmehr; Antonio Iavarone; Roel G W Verhaak
Journal:  Cell       Date:  2022-05-31       Impact factor: 66.850

6.  Cancer Immunoediting in the Era of Immuno-oncology.

Authors:  Matthew M Gubin; Matthew D Vesely
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

Review 7.  Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Madeline Dunterman; Peiwen Chen
Journal:  Trends Pharmacol Sci       Date:  2022-05-07       Impact factor: 17.638

Review 8.  Is there a role for neoadjuvant anti-PD-1 therapies in glioma?

Authors:  Lu Sun; Thomas J Lai; Robert M Prins
Journal:  Curr Opin Neurol       Date:  2021-12-01       Impact factor: 5.710

9.  Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis.

Authors:  Francesca Bufalieri; Irene Basili; Lucia Di Marcotullio; Paola Infante
Journal:  Front Mol Neurosci       Date:  2021-07-08       Impact factor: 5.639

10.  From blood to brain: blood cell-based biomimetic drug delivery systems.

Authors:  Yong-Jiang Li; Jun-Yong Wu; Jihua Liu; Xiaohan Qiu; Wenjie Xu; Tiantian Tang; Da-Xiong Xiang
Journal:  Drug Deliv       Date:  2021-06-18       Impact factor: 6.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.